CONMED

CONMED is a well-established, publicly traded medical device company with a 50+ year history of developing and commercializing surgical technologies for orthopedic and general surgery. Its strategy centers on continuous innovation within its core platforms—notably the AirSeal® insufflation system and its comprehensive energy portfolio—while expanding through strategic acquisitions. The company has achieved consistent revenue growth by addressing unmet clinical needs in surgical access, visualization, and tissue management, positioning itself as a key enabler of modern surgical workflows.

A portfolio of integrated surgical technologies focused on advanced insufflation (AirSeal®), energy-based tissue management, specialized orthopedic implants, and fluid management systems designed to streamline surgical workflows and improve patient outcomes.

CONMED competes against medtech giants like Medtronic, J&J, and Stryker, as well as focused players like Arthrex. It differentiates through surgeon-focused innovation in niche areas (e.g., valveless insufflation, Nitinol implants), integrated product suites, and a value-oriented commercial approach.